|
Peter Sears recently joined Quaker BioVentures to manage BioAdvance Ventures. He was the founder and president of S.R. One, Glaxo SmithKline's venture capital fund, for fourteen years through May 1999, during which, the fund invested over $260 million in more than ninety early-stage biomedical companies. He spent most of his career at SmithKline, starting as an attorney in the company's law department in 1963, moving ten years later into international management where he was general manager in Japan and Korea and later vice president for the company's consumer products division in Canada and Asia. He then became vice president, corporate development, and served in that role for seven years before starting S.R. One. He is currently a director of four young biomedical companies, Avant Immunotherapeutics, Protez Pharmaceuticals, Smart Bioscience, and Viral Therapeutics. He is a graduate of Colgate University and has a J.D. degree from Harvard Law School. | 